CytomX Therapeutics Inc (nasdaq:CTMX) Share Price

Company Profile

Business description
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Contact
151 Oyster Point Boulevard
Suite 400
South San FranciscoCA94080
USA
T: +1 650 515-3185
E: [email protected]
https://www.cytomx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
121

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,088.50	34.00	-0.37%
CAC 40	7,854.61	36.39	0.47%
DAX 40	23,674.53	315.35	1.35%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,228.11	32.45	0.35%
HKSE	26,548.27	109.76	0.42%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,652.08	749.81	1.67%
NZX 50 Index	13,222.12	12.77	-0.10%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,800.00	48.50	-0.55%
SSE Composite Index	3,822.12	9.54	-0.25%